Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors

被引:38
|
作者
Miaskowski, Christine [1 ]
Paul, Steven M. [1 ]
Mastick, Judy [1 ]
Abrams, Gary [2 ]
Topp, Kimberly [2 ]
Smoot, Betty [2 ]
Kober, Kord M. [1 ]
Chesney, Margaret [2 ]
Mazor, Melissa [1 ]
Mausisa, Grace [1 ]
Schumacher, Mark [2 ]
Conley, Yvette P. [3 ]
Sabes, Jennifer Henderson [2 ]
Cheung, Steven [2 ]
Wallhagen, Margaret [1 ]
Levine, Jon D. [2 ,4 ]
机构
[1] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Med, San Francisco, CA USA
[3] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA
[4] Univ Calif San Francisco, Sch Dent, San Francisco, CA USA
基金
美国国家卫生研究院;
关键词
Stress; chemotherapy; peripheral neuropathy; hearing loss; tinnitus; cancer survivor; QUALITY-OF-LIFE; CHRONIC PAIN; HEARING-LOSS; EVENT SCALE; PSYCHOLOGICAL STRESS; TINNITUS SUFFERERS; SOCIAL SUPPORT; DEPRESSION; IMPACT; PREVALENCE;
D O I
10.1016/j.jpainsymman.2018.02.021
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. The most common adverse effects from neurotoxic chemotherapy are chemotherapy-induced neuropathy (CIPN), hearing loss, and tinnitus. Although associations between perceived stress and persistent pain, hearing loss, and tinnitus are documented, no studies have examined these associations in cancer survivors who received neurotoxic chemotherapy. Objectives. In this cross-sectional study, we evaluated for associations between perceived stress and the occurrence of CIPN, hearing loss, and tinnitus, in 623 adult cancer survivors who received platinum and/or taxane compounds. Methods. Survivors completed self-report measures of hearing loss, tinnitus, and perceived stress (i.e., Impact of Events Scale Revised LIES-RD. Separate logistic regression analyses were done for each neurotoxicity to evaluate whether each of the IES-R subscale (i.e., intrusion, avoidance, hyperarousal) and total scores made a significant independent contribution to neurotoxicity group membership. Results. Of the 623 survivors in this study, 68.4% had CIPN, 34.5% reported hearing loss, and 31.0% reported tinnitus. Older age, higher body mass index, poorer functional status, being born prematurely, cancer diagnosis, and higher intrusion (P = 0.013), hyperarousal (P = 0.014), and total (P = 0.047) IES-R scores were associated with CIPN. Older age, being male, poorer functional status, a worse comorbidity profile, and a higher IES-R hyperarousal (P = 0.007) score were associated with hearing loss. Being male, having less education, a worse comorbidity profile, and a higher IES-R hyperarousal (P = 0.029) score were associated with tinnitus. Conclusion. These findings suggest that increased levels of perceived stress are associated with the most common chemotherapy-induced neurotoxicities. (C) 2018 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:88 / 97
页数:10
相关论文
共 50 条
  • [11] Acupuncture and Reflexology for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer
    Ben-Horin, Idan
    Kahan, Peretz
    Ryvo, Larisa
    Inbar, Moshe
    Lev-Ari, Shahar
    Geva, Ravit
    INTEGRATIVE CANCER THERAPIES, 2017, 16 (03) : 258 - 262
  • [12] The effects of kinesiotherapy in cancer patients with chemotherapy-induced peripheral neuropathy
    Bakalidou, D.
    Stasi, S.
    Papagiannis, G.
    Triantafyllou, A.
    ARCHIVES OF HELLENIC MEDICINE, 2023, 40 (01): : 19 - 28
  • [13] Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer
    Kanda, K.
    Fujimoto, K.
    Mochizuki, R.
    Ishida, K.
    Lee, B.
    BMC CANCER, 2019, 19 (01)
  • [14] Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
    Burgess, Jamie
    Ferdousi, Maryam
    Gosal, David
    Boon, Cheng
    Matsumoto, Kohei
    Marshall, Anne
    Mak, Tony
    Marshall, Andrew
    Frank, Bernhard
    Malik, Rayaz A.
    Alam, Uazman
    ONCOLOGY AND THERAPY, 2021, 9 (02) : 385 - 450
  • [15] Chemotherapy-induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes
    Trendowski, Matthew R.
    Lusk, Christine M.
    Ruterbusch, Julie J.
    Seaton, Randell
    Simon, Michael S.
    Greenwald, Mark K.
    Harper, Felicity W. K.
    Beebe-Dimmer, Jennifer L.
    Schwartz, Ann G.
    CANCER MEDICINE, 2021, 10 (22): : 8151 - 8161
  • [16] Chemotherapy-induced peripheral neuropathy onset is associated with early risk of depression and anxiety in breast cancer survivors
    McNeish, Brendan L.
    Richardson, James K.
    Whitney, Daniel G.
    EUROPEAN JOURNAL OF CANCER CARE, 2022, 31 (06)
  • [17] Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors
    Kober, Kord M.
    Mazor, Melissa
    Abrams, Gary
    Olshen, Adam
    Conley, Yvette P.
    Hammer, Marilyn
    Schumacher, Mark
    Chesney, Margaret
    Smoot, Betty
    Mastick, Judy
    Paul, Steven M.
    Levine, Jon D.
    Miaskowski, Christine
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2018, 56 (06) : 908 - +
  • [18] Chemotherapy-induced peripheral neuropathy and its determinants among adult cancer patients on chemotherapy in northwest Ethiopia oncology centers, 2022
    Habtie, Tesfaye Engdaw
    Abate, Melsew Dagne
    Abebe, Gebremeskel Kibret
    Wolie, Zenaw Tessema
    Alamaw, Addis Wondmagegn
    Mitiku, Haymanot Zeleke
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [19] The Experience of Chemotherapy-induced Peripheral Neuropathy in People with Cancer
    Oh, Pok Ja
    Choi, Eun Sook
    Lee, Jin
    ASIAN ONCOLOGY NURSING, 2019, 19 (02) : 81 - 89
  • [20] Experiences of cancer survivors with chemotherapy-induced peripheral neuropathy in the Netherlands: symptoms, daily limitations, involvement of healthcare professionals, and social support
    van de Graaf, Danielle L.
    Engelen, Vivian
    de Boer, Aize
    Vreugdenhil, Gerard
    Smeets, Tom
    van der Lee, Marije L. L.
    Trompetter, Hester R. R.
    Mols, Floortje
    JOURNAL OF CANCER SURVIVORSHIP, 2024, 18 (05) : 1630 - 1639